Immunotherapy and targeted therapy before head and neck cancer surgery
Part of Cancer clinical trials.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of head and neck cancer (mouth, throat, voice box) that can be removed with surgery.
- Your cancer is stage III or IV and you have not had any previous treatment for this cancer.
- You are generally in good health (able to do daily activities without help), with no serious heart, lung, or liver problems.
- You do not have an active autoimmune disease or an active infection like hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two immunotherapy drugs (ivonescimab vs. pembrolizumab) given before and after surgery for head and neck cancer that can be surgically removed. The goal is to see which drug works better to shrink the tumor and prevent the cancer from coming back.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This trial tests whether combining an immunotherapy drug (camrelizumab) with another targeted therapy or chemotherapy given before and after surgery can improve outcomes for people with locally advanced head and neck cancer. It aims to see if this approach is more effective than standard treatments.
This trial tests two drugs—camrelizumab (an immunotherapy) and dalpiciclib (a targeted therapy)—given before surgery for head and neck squamous cell carcinoma that can be removed. The goal is to see if this combination helps shrink the tumor and improves outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.